Ask Warren

Oncocross

382150 · KOSDAQ · ₩382150 · 온코크로스

₩3,030▼ ₩115 (3.66%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩58M₩167M₩141M₩29M₩138M₩63M₩655M₩183M
Cost of sales———₩24M₩12M₩17M₩164M₩78M
Gross profit———₩4.9M₩126M₩45M₩491M₩105M
Operating income−₩2.7B−₩2.5B−₩2.2B−₩2.4B−₩1.9B−₩2.4B−₩2.4B−₩1.5B
Net income₩3.6B−₩2.6B−₩2.9B−₩2B−₩1.8B−₩2.3B−₩2.3B−₩1.4B
Net income to shareholders₩1B−₩2.6B−₩2.9B−₩2B−₩1.8B−₩2.3B−₩2.3B−₩1.4B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩32B₩35B₩29B₩32B₩18B₩20B₩23B₩14B
Current assets₩27B₩28B₩24B₩28B₩16B₩17B₩21B₩13B
Cash and equivalents₩285M₩1.4B₩2.8B₩6.7B₩1.1B₩3.7B₩15B₩5B
Total liabilities₩19B₩23B₩16B₩16B₩1.2B₩1.2B₩2.1B₩1.5B
Current liabilities₩19B₩7.5B₩5.8B₩2.9B₩1.1B₩1B₩1.8B₩1.4B
Borrowings₩8.6B₩8.2B₩5B₩4.7B₩597M₩480M₩636M₩42M
Total equity₩14B₩12B₩13B₩16B₩17B₩18B₩20B₩13B
Shareholders' equity₩14B₩12B₩13B₩16B₩17B₩18B₩20B₩13B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩2B−₩1.7B−₩2.5B−₩876M−₩1.1B−₩2.9B−₩2B−₩456M
Free cash flow−₩2B−₩1.7B−₩2.5B−₩876M−₩1.1B−₩2.9B−₩2B−₩456M

Consolidated where available. Amounts in won.

Also known as: Oncocross / 온코크로스 / 382150 / KRX:382150

Source: KRX statistical information